Ranitidine
H2-Receptor Antagonists
Sold as ACID REDUCER · MAXIMUM STRENGTH ACID…
- Drug class
- H2-Receptor Antagonists
- Availability
- Prescription and OTC
- Routes
- Oral
- Markets covered
- 3
- Products on record
- 16
- FDA reports (12 mo)
- 1,332
Overview
Plain-language summary, compiled from the cited regulatory records
Ranitidine is an H2-receptor antagonist [1]. It is approved for relieving and preventing heartburn associated with acid indigestion and sour stomach [1]. This includes heartburn brought on by consuming certain foods and beverages [1].
Ranitidine has been marketed under various brand names [1]. In the past 12 months, there have been 1332 adverse event reports associated with ranitidine [2]. The most frequent reactions reported include off-label use, pain, rash, reports of the drug being ineffective, and infusion-related reactions [2].
This is not medical advice. Consult a qualified healthcare professional.
Regulatory status by market
| Market | Regulator | Products | Last revision |
|---|---|---|---|
| CA Canada | Health Canada | 7 | November 24, 2025 |
| GB United Kingdom | MHRA | 6 | February 27, 2026 |
| US United States | FDA | 3 | December 5, 2025 |
CACanada· Health Canada
7 products
Uses
8 DOSAGE AND ADMINISTRATION ......................................................................... 11 OVERDOSAGE ......................................................................................................... 11 ACTION AND CLINICAL PHARMACOLOGY.........................................................
12 STORAGE AND STABILITY .................................................................................... 16 DOSAGE FORMS, COMPOSITION AND PACKAGING .......................................... 16 PART II: SCIENTIFIC INFORMATION .........................................................................
18 PHARMACEUTICAL INFORMATION ..................................................................... 18 CLINICAL TRIALS ................................................................................................... 19 DETAILED PHARMACOLOGY................................................................................
GBUnited Kingdom· MHRA
6 products
Uses
Adults Zantac Tablets are indicated for: • treatment of duodenal ulcer and benign gastric ulcer, including that associated with non- steroidal anti-inflammatory agents. • treatment of duodenal ulcers associated with Helicobacter pylori infection.
• treatment of post-operative ulcer • Zollinger-Ellison syndrome • oesophageal reflux disease • chronic episodic dyspepsia, characterised by pain (epigastric or retrosternal) which is related to meals or disturbs sleep but is not associated with the preceding conditions may benefit from ranitidine treatment.
Zantac Tablets are indicated for the following conditions where reduction of gastric secretion and acid output is desirable: • prophylaxis of gastrointestinal haemorrhage from stress ulceration in seriously ill patients • prophylaxis of recurrent haemorrhage in patients with bleeding peptic ulcers • before general anaesthesia in patients considered to be at risk of acid aspiration (Mendelson's syndrome), particularly obstetric patients during labour.
USUnited States· FDA
3 products
Uses
Use(s) relieves heartburn associated with acid indigestion and sour stomach prevents heartburn associated with acid indigestion and sour stomach brought on by eating or drinking certain foods and beverages
How to take
Drug interactions
Known interactions involving Ranitidine. Select one for details. This list is informational and not a complete interaction checker.
Showing 240 of 581. Type above to find a specific drug.
Interaction data compiled from DDInter (academic, CC-BY). Severity classification only - this is not a complete interaction checker and not medical advice.
Sources & citations
- [1]Health Canada (DPD) · 02293471 · revised November 24, 2025
- [2]MHRA (UK) · PL109490043 · revised April 8, 2022
- [3]FDA DailyMed · 00df8a42-296f-80… · revised May 23, 2025 [PDF]
- [4]OpenFDA adverse-event reports (US), 12 months ending June 4, 2026.
Information on this page is compiled from public regulatory records. Drugvu is not affiliated with any regulator or pharmaceutical manufacturer. This is not medical advice. Always consult a qualified healthcare professional.